US EditionNew Molecule Offers a More Targeted and Potent Immunotherapy
The fusion protein selectively activates tumor-killing immune cells and blocks cancer immune evasion, with promising phase I clinical trial results led by Roche.
2 Articles
2 Articles
New molecule offers a more targeted and potent immunotherapy
A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel, Switzerland, have demonstrated that this fusion protein can both block the "do not attack" signal used by cancer cells and selectively activate tumor-fighting immune cells. This dual action could pave the way for more effective cancer therapies with fewer side effects.
Stronger together: A new fusion protein boosts cancer immunotherapy
A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel, Switzerland, have demonstrated that this fusion protein can both block the "do not attack" signal used by cancer cells and selectively activate tumor-fighting immune cells. This dual action could pave the way for more effective cancer therapies with fewer side effects.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
